Ral GTPases in tumorigenesis: Emerging from the shadows
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Oncogenic Ras proteins rely on a series of key effector pathways to drive the physiological changes that lead to tumorigenic growth. Of these effector pathways, the RalGEF pathway, which activates the two Ras-related GTPases RalA and RalB, remains the most poorly understood. This review will focus on key developments in our understanding of Ral biology, and will speculate on how aberrant activation of the multiple diverse Ral effector proteins might collectively contribute to oncogenic transformation and other aspects of tumor progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis
Guo, J. Y., Chen, H.-Y., Mathew, R., Fan, J., Strohecker, A. M., Karsli-Uzunbas, G., Kamphorst, J. J., Chen, G., Lemons, J. M. S., Karantza, V., et al. (2011) · Genes & Development · doi:10.1101/gad.2016311 · Cited by 1,323
The exocyst is a Ral effector complex
Moskalenko, S., Henry, D. O., Rosse, C., Mirey, G., Camonis, J. H., & White, M. A. (2002) · Nature Cell Biology · doi:10.1038/ncb728 · Cited by 423 · cited 2×
“targeted delivery of secretory vesicles to specific membrane compartments, such as the basolateral surface of polarized epithelial cells [57,58].”
BackgroundActivation of RalA is critical for Ras-induced tumorigenesis of human cells
Lim, K.-H., Baines, A. T., Fiordalisi, J. J., Shipitsin, M., Feig, L. A., Cox, A. D., Der, C. J., & Counter, C. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.030 · Cited by 355 · cited 4×
“Studies performed on human cells on the other hand have consistently shown that inhibition of RalA alone, but not RalB, is sufficient to inhibit tumor initiation [15,16,18,35], while inhibition of RalB inhibits invasion and metastasis [16–18,36].”
BackgroundInfluentialBridging Ral GTPase to Rho Pathways
Jullien-Flores, V., Dorseuil, O., Romero, F., Letourneur, F., Saragosti, S., Berger, R., Tavitian, A., Gacon, G., & Camonis, J. H. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.38.22473 · Cited by 338
Cantor, S. B., Urano, T., & Feig, L. A. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.8.4578 · Cited by 310
Activated Ras interacts with the Ral guanine nucleotide dissociation stimulator.
Hofer, F., Fields, S., Schneider, C., & Martin, G. S. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.11089 · Cited by 287
The exocyst complex binds the small GTPase RalA to mediate filopodia formation
Sugihara, K., Asano, S., Tanaka, K., Iwamatsu, A., Okawa, K., & Ohta, Y. (2002) · Nature Cell Biology · doi:10.1038/ncb720 · Cited by 258 · cited 2×
“targeted delivery of secretory vesicles to specific membrane compartments, such as the basolateral surface of polarized epithelial cells [57,58].”
BackgroundSmall G protein Ral and its downstream molecules regulate endocytosis of EGF and insulin receptors
Nakashima, S., Morinaka, K., Koyama, S., Ikeda, M., Kishida, M., Okawa, K., Iwamatsu, A., Kishida, S., & Kikuchi, A. (1999) · The EMBO Journal · doi:10.1093/emboj/18.13.3629 · Cited by 231 · cited 1×
“A large protein with a number of protein-protein interaction domains, RalBP1 has been shown to act as a bridge between CyclinB/Cdk1 and at least two of its substrates, Drp1 [41] and Epsin [74], and also promotes the assembly of the endocytic machinery [48,50].”
BackgroundJullien-Flores, V., Mahé, Y., Mirey, G., Leprince, C., Meunier-Bisceuil, B., Sorkin, A., & Camonis, J. H. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.16.2837 · Cited by 186
Novel function of human RLIP76: ATP-dependent transport of glutathione conjugates and doxorubicin
Awasthi, S., Cheng, J., Singhal, S. S., Saini, M. K., Pandya, U., Pikula, S., Bandorowicz-Pikula, J., Singh, S. V., Zimniak, P., & Awasthi, Y. C. (2000) · Biochemistry · doi:10.1021/bi992964c · Cited by 159
Cited by
Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma
Gillette, M. A., Satpathy, S., Cao, S., Dhanasekaran, S. M., Vasaikar, S. V., Krug, K., Petralia, F., Li, Y., Liang, W.-W., Reva, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.013 · Cited by 820
“Ras-related protein Ral-A (RALA) is a GTPase that has been shown to mediate oncogenic signaling and regulate EGFR and KRASmutation-mediated tumorigenesis (Gildea et al., 2002; Kashatus, 2013; Peschard et al., 2012).”
BackgroundStephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795
Therapeutic strategies to target RAS-mutant cancers
Ryan, M. B., & Corcoran, R. B. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0105-0 · Cited by 420
Ral signaling pathway in health and cancer
Moghadam, A. R., Patrad, E., Tafsiri, E., Peng, W., Fangman, B., Pluard, T. J., Accurso, A., Salacz, M., Shah, K., Ricke, B., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1105 · Cited by 58
Ebi, H., Faber, A. C., Engelman, J. A., & Yano, S. (2014) · Cancer Science · doi:10.1111/cas.12383 · Cited by 18
Metadata
- Authors
- Kashatus, D. F.
- Venue
- Experimental Cell Research
- Publisher
- Elsevier BV
- Published
- 2013-09
- Volume
- 319
- Issue
- 15
- Pages
- 2337-2342
- ISSN
- 0014-4827 (ISSN-L)
- OpenAlex
- W2031552936
- Cited by
- 60
- References
- 19
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ral GTPases in tumorigenesis: Emerging from the shadows. https://app.cochat.ai/papers/10.1016/j.yexcr.2013.06.020
- The paper
- Kashatus, D. F. (2013). Ral GTPases in tumorigenesis: Emerging from the shadows. Experimental Cell Research. https://doi.org/10.1016/j.yexcr.2013.06.020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.